It's BMS vs. Celgene investors once more after US appeals court revives lawsuit

A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-playing the approval of blood cancer drug Breyanzi to avoid paying out a more than $6 billion contingent value right.